key: cord-1056433-qbg5dul5
authors: Mert, Kadir Ugur; Turk, Ugur Onsel; Gorenek, Bulent
title: A statistical perspective to the QTc interval in the treatment of COVID-19
date: 2021-03-16
journal: J Electrocardiol
DOI: 10.1016/j.jelectrocard.2021.03.002
sha: 533e276dcb594bdb49d05e312d0729c069639873
doc_id: 1056433
cord_uid: qbg5dul5

nan

In the methodology section high risk QTc pattern determined as a peak QTc ≥ 500 ms and those with an increase in the QTc ≥ 60 ms from baseline values. [1] However, according to literature it should be defined "as a peak QTc ≥ 500 ms and/or those with an increase in the QTc ≥ 60 ms from baseline values". It may be only a typing error but it must be corrected because it alters the results and precision of the study. Furthermore, the statistically significant threshold of p value was not mentioned in the methodology. It was demonstrated in the table 1 that other QTc prolonging therapy (levofloxacin, amiodarone, olanzepine, haloperidol etc.) significantly higher in double therapy group (33.3% vs 17.3%; p=0.021). [1] Baseline characteristics of the groups, namely medications, were different and this needs to be discussed more detailed in the manuscript.

The authors compared change in QTc between treatment groups and found no difference by an unpaired T test (31.2 ± 30.6 ms vs 29.8 ± 36.5 ms; p=0.813). However, standard deviations of ΔQTc values higher than mean values which indicates the skewed distribution. As a rule of thumb, it is customary to use the median instead of the mean if the data is not normally distributed. [2] ΔQTc values should be depicted as medians and interquartile range and non-parametric tests should be performed rather than a T test. [3] Therefore, we wonder whether there were any differences in ΔQTc value with any statistical mixed effects model. Moreover, the results are certainly subject to statistical power and Type I error rates due to unequal sizes and variances (n=54 vs n=114). [4, 5] Finally, the authors also were not present any detail about intra-and interobserver variability in QTc measurement in their study. Regarding to the subjective evaluation of very sensitive surrogate marker such as QTc interval, we think that these values should be presented in the results section.

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19

Is electrical cardioversion doable in atrial fibrillation without transesophageal echocardiography?

Statistics notes: Analysing controlled trials with baseline and follow up measurements

Impact of Sample Size and Variability on the Power and Type I Error Rates of Equivalence Tests: A Simulation Study. Practical Assessment, Research, and Evaluation

Comparison of acute management of atrial fibrillation in heart failure with unequal sized groups